Columbia Labs won't give up on controlled-release vaginal gel

Columbia Laboratories ($CBRX) is slashing 42% of its workforce in light of the FDA's recent rejection of a vaginal progesterone gel it is developing with Watson Pharmaceuticals ($WPI). The product incorporates Columbia's bioadhesive drug delivery technology, which uses the bioadhesive polymer polycarbophil to bond to mucosal surfaces in the body, after which it discharges the drug it carries using controlled release. Columbia is making the majority of its 10 cuts in research and development and administration; 24 positions will remain. Moving forward, the company said it is considering "all strategic options" and will continue to try advancing its vaginal progesterone gel to regulatory approval. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.